\tXingxu Medical operates production bases in the Northwest and East China regions, represented by its Xi 'an and Suzhou factories respectively. The Shaanxi Xingxu Kangda Medical Technology Co., Ltd. in the Northwest region is located in the Xinfeng Industrial Park of Lintong District, Xi' an, the ancient capital of thirteen dynasties. With a registered capital of 20 million yuan and a land area of 7 mu (approximately 0.5 hectares), this modern industrial base covers over 12,000 square meters. It includes 6,000+ square meters of GMP-compliant cleanrooms, 500 square meters of infusion laboratories, 700 square meters of fully automated sterilization facilities, 3,000+ square meters of storage areas, and 2,000+ square meters of office space. The East China branch, Xingxu Medical Devices (Suzhou) Co., Ltd., is situated in Zhangpu Town, Kunshan City, Jiangsu Province, within the German Industrial Park. With a registered capital of 125 million yuan and a land area exceeding 15,000 square meters, it features multiple fully automated safety self-destruct syringe production lines and standardized medical device laboratories. These two production bases complement each other, forming a multi-regional collaborative production network, precise logistics coordination for central-western regions, and an efficient, convenient medical device supply chain system.
\tXingxu Medical adheres to the core value of "making global healthcare safer." From its inception, the company established the strategic concept of "initiating a new era of safe injections," focusing on the research, development, and production of precision medical consumables for safety. The company's independently developed "retractable self-destruct syringe series" has obtained invention patent certifications in 54 countries and regions worldwide. Its unique triple safety locking and needle self-tilt
technology effectively achieve zero needle exposure and prevent reuse, minimizing the risk of needlestick injuries to medical staff. This technological breakthrough filled a gap in China's safe syringe market. Since its establishment, the company has successively obtained ISO-13485 medical device quality management system certification, a Class III medical device product registration certificate issued by the National Medical Products Administration (CFDA), and passed the EU MDR certification and US FDA approval, becoming one of the first Chinese brands to enter the high-end medical markets of Europe and America.
\tThe company has established a full chain quality control system from raw material traceability to terminal sterilization, from the selection of medical grade polypropylene composite materials to precision injection molding, from the mature application of AI vision detection technology to achieve zero leakage of millions of products in fully automated assembly, to the intelligent sterilization system of ethylene oxide. All self-developed software systems can achieve data collection throughout the entire process, ensuring comprehensive monitoring and traceability of the production process, and achieving international leading level of product yield control.
\tTo meet the global demand for safety syringe market with an average annual growth rate of 15%, Xingxu Medical has developed a "trinity" development strategy:
\t1. Technology Export: Establish a global technology service center in Xi'an headquarters to provide "whole factory export" solutions for customers in various regions worldwide. The first whole factory export project overseas is expected to be put into operation in 2026;
\t2. Product matrix: Invest 320 million yuan to build the second phase of smart factory, expand the product line of safe injection and safe blood collection, and form a complete product ecology covering prevention, testing, treatment and innovative manufacturing of high-end consumables;
\t3. Industry-university-research collaboration: Jointly establish the "Medical Polymer Materials and Medical Consumables Joint Development Laboratory" with universities in Xi'an to advance cutting-edge technologies for raw materials and medical devices.
\tBased in Xi 'an, serving the world. Xingxu Medical will continue to drive innovation with technological advancement and take quality and safety as the foundation, striving to become a benchmark enterprise in the global safe injection field, contributing China's wisdom to building a global community of health for all.
\tOver the next three years, the company will accelerate its global expansion strategy. Building upon its Xi'an facility, we will continuously optimize our industrial chain to deliver complete safety syringe manufacturing processes and high-quality production technologies to global clients, thereby creating greater industrial value worldwide. Our goal is to achieve an annual production capacity of 9 billion units within three years, with products reaching over 80 countries and regions. As a "Pioneer in Safe Injection", Xingxu Medical will help global healthcare systems transition into a new era of safe injection technology. This initiative aims to eliminate the fear of needlestick injuries among medical professionals worldwide, reduce waste of global medical resources, and illuminate every corner of the world with the dawn of safe injection technology in healthcare.